(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.93%) $83.07
(-1.16%) $1.619
(-0.28%) $2 340.70
(0.05%) $27.55
(0.56%) $927.30
(-0.17%) $0.933
(-0.15%) $11.01
(-0.24%) $0.798
(0.00%) $92.17
Live Chart Being Loaded With Signals
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases...
Stats | |
---|---|
本日の出来高 | 548.00 |
平均出来高 | 1 511.00 |
時価総額 | 10.04B |
Last Dividend | $0.324 ( 2023-06-02 ) |
Next Dividend | $0 ( N/A ) |
P/E | 15.10 |
ATR14 | $0 (0.00%) |
Ipsen S.A. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Ipsen S.A. 財務諸表
Annual | 2023 |
収益: | $3.13B |
総利益: | $2.35B (75.10 %) |
EPS: | $7.79 |
FY | 2023 |
収益: | $3.13B |
総利益: | $2.35B (75.10 %) |
EPS: | $7.79 |
FY | 2022 |
収益: | $3.16B |
総利益: | $2.63B (83.28 %) |
EPS: | $1.970 |
FY | 2021 |
収益: | $3.00B |
総利益: | $2.46B (82.06 %) |
EPS: | $1.948 |
Financial Reports:
No articles found.
Ipsen S.A. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.324 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.262 | 2013-06-11 |
Last Dividend | $0.324 | 2023-06-02 |
Next Dividend | $0 | N/A |
Payout Date | 2023-06-27 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $3.05 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.56 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.15 | |
Div. Directional Score | 9.82 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WRTBY | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
MCHB | Ex Dividend Knight | 2023-08-09 | Annually | 0 | 0.00% | |
CNAF | Ex Dividend Knight | 2023-08-24 | Quarterly | 0 | 0.00% | |
SONVY | Ex Dividend Knight | 2023-06-14 | Annually | 0 | 0.00% | |
HEGIY | Ex Dividend Knight | 2023-09-15 | Semi-Annually | 0 | 0.00% | |
ANIOY | Ex Dividend Knight | 2023-07-13 | Annually | 0 | 0.00% | |
NODB | Ex Dividend Junior | 2023-10-17 | Quarterly | 0 | 0.00% | |
CUYTY | Ex Dividend Junior | 2023-09-29 | Annually | 0 | 0.00% | |
THUPY | Ex Dividend Knight | 2023-10-04 | Semi-Annually | 0 | 0.00% | |
IESFY | Ex Dividend Knight | 2023-05-16 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.206 | 1.500 | 5.88 | 8.82 | [0 - 0.5] |
returnOnAssetsTTM | 0.102 | 1.200 | 6.60 | 7.92 | [0 - 0.3] |
returnOnEquityTTM | 0.178 | 1.500 | 9.13 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.155 | -1.000 | 8.45 | -8.45 | [0 - 1] |
currentRatioTTM | 1.167 | 0.800 | 9.17 | 7.33 | [1 - 3] |
quickRatioTTM | 0.864 | 0.800 | 9.63 | 7.70 | [0.8 - 2.5] |
cashRatioTTM | 0.325 | 1.500 | 9.31 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0626 | -1.500 | 8.96 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 37.44 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.20 | 2.00 | 6.60 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 7.99 | 2.00 | 6.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.103 | -1.500 | 9.59 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.817 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.314 | 1.000 | 5.73 | 5.73 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.13 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.495 | 0.800 | -0.0358 | -0.0286 | [0.5 - 2] |
Total Score | 13.49 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.64 | 1.000 | 9.73 | 0 | [1 - 100] |
returnOnEquityTTM | 0.178 | 2.50 | 9.44 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 7.99 | 2.00 | 7.34 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.142 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.20 | 2.00 | 6.60 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.155 | 1.500 | 8.45 | -8.45 | [0 - 1] |
pegRatioTTM | 0.0973 | 1.500 | -2.68 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.270 | 1.000 | 5.76 | 0 | [0.1 - 0.5] |
Total Score | 6.15 |
Ipsen S.A.
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。